Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth for nearly twice as long as a placebo, researchers from Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania announced as they reported on a randomized phase III trial at the ASCO Annual Meeting in Chicago, Illinois. If the US FDA (Food and Drug Administration) approves liver and kidney cancer drug Nexavar for use in radioactive iodine-refractory differentiated thyroid cancer, it would be the first effective agent for this disease...
More...
More...